CAR-T cell therapy is a targeted, personalised therapy that contains patients’ autologous T cells reengineered to fight cancer. This living drug continues to exist in the body and combat cancer long after its infusion.
Personalised: Establishes individual treatments for individual patients1
Reengineered: Harnesses the power of our existing defense mechanisms to fight cancer1
Persistent: Provides hope for long-lasting efficacy to relapsed or refractory patients who need it most1
The structure of CAR-T cells1
CAR-T cell therapy contains patients’ autologous T cells that are modified to express the CD19 chimeric antigen receptor (CAR), which helps eliminate B cells, including those that are malignant. Current CAR-T cell therapies contain CARs composed of five parts. Please see the diagram and accompanying text below to learn more about the function of each component.
Extracellular receptor that binds to the targeted antigen
Extracellular hinge component that provides flexibility to enhance binding affinity
Transmembrane domain that anchors the molecule to the T cell
Intracellular costimulatory domain that enhances CAR-T cell persistence
Intracellular signaling domain that initiates the biochemical cascade leading to immune activation
CARs can have different costimulatory domains. Two such costimulatory domains are 4-1BB and CD28. See the table below for some characteristics of 4-1BB- and CD28-containing CARs.
Enhances CAR-T cell expansion and long-term persistence2,3
Enhances early and rapid CAR-T cell expansion in vivo and in vitro2,6
Demonstrated induction of central memory T-cell differentiation for improved proliferative potential in vitro3,4
Correlated with effector memory T-cell differentiation for immediate protection in vitro3
May help prevent CAR-T cell exhaustion1,5
Provides limited long-term persistence and can cause rapid CAR-T cell exhaustion5
To learn more broadly about the field of cell and gene therapy and the difference between the two, please click here.
Potentially definitive treatment1
The CAR-T cell therapy patient population is often heavily pretreated and in need of an effective, durable treatment option. CAR-T cell therapy is a breakthrough treatment that offers a unique approach to fighting cancer.7 Patients may not require another treatment after CAR-T cell therapy, especially if they achieved a complete response or complete remission (CR).1
Deeper responses to CAR-T cell therapy correlate with durable efficacy. For patients with leukaemia, minimal residual disease negative (MRD–) status is tied to positive outcomes.8
Identifying appropriate patients
CAR-T cell therapy offers a new treatment option for some patients who have not responded (refractory) following therapy or who have relapsed following two or more prior therapies, including stem cell transplant (SCT). Patients who are not suitable for SCT due to performance status, comorbidities, or inability to achieve CR may be eligible for CAR-T cell therapy.1,9
Selecting appropriate patients is important, as the following characteristics may impact how patients respond to CAR-T cell therapy10,11:
Number of prior therapies11
Some benefits of CAR-T cell therapy include the fact that patients do not need to be in CR to initiate treatment and that no donor is required for treatment.1
Manageable safety profile1
CAR-T cell therapy has a different side effect profile than other treatment options. Please click here to view the treatment landscape. Possible side effects of CAR-T therapy include cytokine release syndrome, neurotoxicity, and hypogammaglobulinemia. Although these side effects can be serious, they are often transient and are typically manageable.
CAR-T cell therapy is not known to be associated with some serious long-term side effects, such as graft-vs-host disease or hair loss.
Some patients who received CAR-T cell therapy reported improvements in quality of life and were able to return to normal activities shortly after infusion. Research into future generations of CAR-T cell therapies aims to further improve upon the efficacy and safety profile of this drug class.12 Please click here to view the future of CAR-T cell therapy.
Kymriah Summary of Product Characteristics. Novartis Pharma AG; 2018.
Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453- 1464.
Kawalekar OU, O’Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380-390.
Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581-590.
Zhao Z, Condomines M, van der Stegen SJC, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415-428.
Leech AA, Dusetzina SB. Cost-effective but unaffordable: the CAR-T conundrum [published online ahead of print December 17, 2018]. J Natl Cancer Inst. doi:10.1093/jnci/djy195.
Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood. 2015;126(8):964-971.
Data on file. CTL019C2201 Oncology Clinical Trial Protocol. March 11, 2015. Novartis Pharmaceuticals Corp; 2015.
Patient selection: the key first step to successful CAR T-cell therapy. Cell Therapy Next. December 2018.
Künkele A, Brown C, Beebe A, et al. Manufacture of chimeric antigen receptor T cells from mobilized cryopreserved peripheral blood stem cell units depends on monocyte depletion. Biol Blood Marrow Transplant. 2019;25(2):223-232.
Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nature. 2016;13:370-383.